2024
CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma
Pal S, Tran B, Haanen J, Hurwitz M, Sacher A, Tannir N, Budde L, Harrison S, Klobuch S, Patel S, Meza L, Dequeant M, Ma A, He Q, Williams L, Keegan A, Gurary E, Dar H, Karnik S, Guo C, Heath H, Yuen R, Morrow P, Agarwal N, Srour S. CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma. Cancer Discovery 2024, 14: of1-of14. PMID: 38583184, PMCID: PMC11215406, DOI: 10.1158/2159-8290.cd-24-0102.Peer-Reviewed Original ResearchClear cell renal cell carcinomaChimeric antigen receptorCAR-T cellsT-cell therapyCell renal cell carcinomaRenal cell carcinomaT cellsCell carcinomaSolid tumorsAllogeneic CAR-T cell therapyChimeric antigen receptor T cellsAdvanced clear cell renal cell carcinomaAllogeneic CAR-T cellsClinical trialsCAR-T cell productsCAR-T cell therapyTreatment of solid tumorsFirst-in-human clinical trialCAR-T constructsDose-limiting toxicityT cell productionNovel treatment optionsTreatment of clear cell renal cell carcinomaHematologic malignanciesAntigen receptor
2023
Assessment of short-chain fatty acid (SCFA) and circulating cytokine trends in a clinical trial of nivolumab/ipilimumab and CBM588 in metastatic renal cell carcinoma (mRCC).
Dizman N, Pathak K, Alcantara M, Meza L, Bergerot P, Willey M, Dorff T, Hsu J, Zengin Z, Castro D, Ebrahimi H, Chehrazi-Raffle A, Tripathi A, Trent J, Takahashi M, Oka K, Higashi S, Kortylewski M, Pirrotte P, Pal S. Assessment of short-chain fatty acid (SCFA) and circulating cytokine trends in a clinical trial of nivolumab/ipilimumab and CBM588 in metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2023, 41: 4556-4556. DOI: 10.1200/jco.2023.41.16_suppl.4556.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaNivolumab/ipilimumabObjective response rateShort-chain fatty acidsPlasma short-chain fatty acidsImmune checkpoint blockadeCheckpoint blockadeCytokine levelsSCFA levelsClinical trialsRandomized phase I clinical trialSarcomatoid Metastatic Renal Cell CarcinomaPhase I clinical trialStool SCFA levelsAcid levelsTreatment-naïve patientsAltered amino acid metabolismRenal cell carcinomaIpilimumab armNaïve patientsButyric acid levelsSerum cytokinesClinical outcomesCell carcinomaBiologic rationaleExamining Exclusion Criteria in Advanced Prostate Cancer Clinical Trials: An Assessment of recommendations From the American Society Of Clinical Oncology and Friends of Cancer Research
Ebrahimi H, Castro D, Feng M, Prajapati S, Lee K, Chan E, Paul T, Sehgal I, Patel J, Li X, Zengin Z, Meza L, Mercier B, Hsu J, Govindarajan A, Chawla N, Dizman N, Bergerot C, Rock A, Liu S, Tripathi A, Dorff T, Pal S, Chehrazi-Raffle A. Examining Exclusion Criteria in Advanced Prostate Cancer Clinical Trials: An Assessment of recommendations From the American Society Of Clinical Oncology and Friends of Cancer Research. Clinical Genitourinary Cancer 2023, 21: e467-e473. PMID: 37301665, DOI: 10.1016/j.clgc.2023.05.013.Peer-Reviewed Original ResearchConceptsProstate cancer clinical trialsHBV/HCV infectionCancer clinical trialsHepatitis B virusClinical trialsConcurrent malignancyBrain metastasesEligibility criteriaHCV infectionHIV infectionExclusion criteriaClinical OncologyEastern Cooperative Oncology Group scaleAssessment of recommendationsECOG PS 0C virus infectionRestrictive eligibility criteriaAmerican SocietyCancer researchHCV positivityPS 0HIV positivityImmunotherapy trialsB virusVirus infectionEvaluation of eligibility criteria in advanced prostate cancer clinical trials based on ASCO-FCR recommendations.
Feng M, Prajapati S, Castro D, Lee K, Chan E, Sehgal I, Patel J, O'Dell A, Zengin Z, Li X, Chehrazi-Raffle A, Dizman N, Tripathi A, Rock A, Liu S, Mercier B, Meza L, Philip E, Dorff T, Pal S. Evaluation of eligibility criteria in advanced prostate cancer clinical trials based on ASCO-FCR recommendations. Journal Of Clinical Oncology 2023, 41: 34-34. DOI: 10.1200/jco.2023.41.6_suppl.34.Peer-Reviewed Original ResearchType of treatmentExclusion criteriaBrain metastasesEligibility criteriaExact testHBV/HCVMetastatic prostate cancerFisher's exact testChi-square testClinical eligibilityConcurrent malignancyHCV positivityHormone therapyHIV positivityCombination therapyRadioligand therapyClinical trialsProstate cancerProstate cancer studyRadiation therapyClinical OncologyTherapyCancer typesMeSH termsPhase I
2022
Characterizing IMDC prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma (mRCC).
Ernst M, Navani V, Wells J, Donskov F, Basappa N, Labaki C, Pal S, Meza L, Wood L, Ernst D, Szabados B, McKay R, Parnis F, Suárez C, Yuasa T, Kapoor A, Alva A, Bjarnason G, Choueiri T, Heng D. Characterizing IMDC prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2022, 40: 308-308. DOI: 10.1200/jco.2022.40.6_suppl.308.Peer-Reviewed Original ResearchInternational mRCC Database ConsortiumMetastatic renal cell carcinomaVascular endothelial growth factor-targeted therapyIpi-nivoImmuno-oncology agentsOverall survivalCombination therapyComplete responseFirst-lineFirst-line treatment of metastatic renal cell carcinomaTreatment of metastatic renal cell carcinomaInternational mRCC Database Consortium criteriaClinical trialsFirst-line combination therapyEfficacy of combination therapyNon-clear cell histologyTherapy to deathFirst-line treatmentLog-rank testRenal cell carcinomaReal-world survivalCell histologySarcomatoid featuresOS outcomesLiver metastases
2021
Characterizing the relationships between tertiary and community cancer providers: Results from a survey of medical oncologists in Southern California
Salgia NJ, Chehrazi‐Raffle A, Hsu J, Zengin Z, Salgia S, Chawla NS, Meza L, Malhotra J, Dizman N, Muddasani R, Ruel N, Cianfrocca M, Gong J, Anand S, Chiu V, Yeh J, Pal SK. Characterizing the relationships between tertiary and community cancer providers: Results from a survey of medical oncologists in Southern California. Cancer Medicine 2021, 10: 5671-5680. PMID: 34331372, PMCID: PMC8366095, DOI: 10.1002/cam4.4119.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAttitude of Health PersonnelCaliforniaCancer Care FacilitiesClinical Trials as TopicCommunicationFemaleHospitals, CommunityHumansIntersectoral CollaborationMaleMiddle AgedNeoplasmsOncologistsReferral and ConsultationSurveys and QuestionnairesTertiary Care CentersConceptsClinical trialsCommunity oncologistsTertiary centerTrial availabilityClinical trial availabilityTertiary cancer centerClinical trial enrollmentRegional tertiary centerCancer providersMost patientsTertiary referralMedical oncologistsReferral patternsTrial enrollmentCancer CenterTertiary practiceCancer carePatient referralMost oncologistsGeneral oncologistsCommon reasonClinical practiceOncologistsPatient careClinical expertiseBridging the gaps between tertiary and community care networks: Results from a southern California survey research analysis.
Chehrazi-Raffle A, Salgia N, Hsu J, Zengin Z, Salgia S, Chawla N, Malhotra J, Dizman N, Muddasani R, Meza L, Cianfrocca M, Gong J, Anand S, Chiu V, Yeh J, Pal S. Bridging the gaps between tertiary and community care networks: Results from a southern California survey research analysis. Journal Of Clinical Oncology 2021, 39: 1538-1538. DOI: 10.1200/jco.2021.39.15_suppl.1538.Peer-Reviewed Original ResearchCommunity oncologistsClinical trialsTertiary centerTrial availabilityCancer CenterCedars-Sinai Medical CenterHope Comprehensive Cancer CenterClinical trial availabilityTertiary cancer centerMajority of patientsClinical trial enrollmentComprehensive cancer centerSource of referralRegional tertiary centerSinai Medical CenterCommunity practicePT referralTertiary referralReferral patternsTrial enrollmentTertiary practiceCommunity care networksGeneral oncologistsMedical CenterCommon reasonBiomarker approach harnessed in trials of personalized medicine for bladder cancer
Dizman N, Meza L, Pal SK. Biomarker approach harnessed in trials of personalized medicine for bladder cancer. Nature Medicine 2021, 27: 761-763. PMID: 33941920, DOI: 10.1038/s41591-021-01300-1.Commentaries, Editorials and Letters